Celltrion accelerates shareholder returns with W400b in buybacks, W200b in cancellations

Celltrion has announced a series of share buybacks and cancellations totaling 400 billion won ($294 million) and 200 billion won, respectively, this year, signaling an aggressive push to boost shareholder value.

The moves back up management's stated commitment to return roughly one-third of annual consolidated net profit to shareholders — a pledge the company is now demonstrating through concrete market action rather than words alone.

Celltrion's board met Tuesday and approved an additional buyback of approximately 100 billion won. The company plans to repurchase 560,853 shares, priced at the closing rate the day before the board resolution, through open-market purchases from Wednesday through Dec. 29.

With this latest decision, Celltrion's confirmed buybacks for the year reach a cumulative 2,135,262 shares, worth 400 billion won in total. On Sept. 16, the company resolved to cancel 544,299 previously acquired shares — worth about 100 billion won — on Wednesday. That brings the total value of share cancellations confirmed this year to approximately 200 billion won across two separate rounds.

Celltrion said it plans to determine how to handle the newly acquired shares — worth 100 billion won — at its annual general meeting in March 2027, where it will consult directly with shareholders. Based on finalized annual earnings and distributable profit, the company will compare the practical impact of share cancellations against expanded cash dividends on shareholder value, gather shareholder input, and adopt whichever option proves more beneficial.

The approach goes beyond a simple share-price defense. By pairing the earlier cancellation resolution — which eliminates overhang risk from potential selling pressure — with a commitment to route the newly acquired shares through a shareholder vote toward either cancellation or higher cash dividends, Celltrion aims to maximize the effectiveness of its return program.

The aggressive return policy is underpinned by record earnings and robust free cash flow. Celltrion posted record sales of 4.16 trillion won and operating profit of 1.17 trillion won last year, and continued its strong growth in the first half of this year with sales of 2.54 trillion won and operating profit of 773.7 billion won. Analysts say the company has secured a solid funding base for shareholder returns, with established cash-cow products such as Remsima and Truxima complemented by a high-margin new portfolio — including Zymfentra, Yuflyma and Vegzelma — that is rapidly expanding its global prescription footprint.

"We believe the share price is undervalued relative to the company's fundamentals and future growth potential, and we are pursuing share-price stability and maximum shareholder value," a Celltrion official said. "We will faithfully honor our commitment to return one-third of net profit, and complete a virtuous cycle in which investment in research and development and production facilities goes hand in hand with shareholder returns."